

Avantor increases global capacity to assist production of biologics and vaccines

27 April 2021 | News

Increases single-use manufacturing footprint and cleanroom space in the U.S. and Europe

Avantor Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, has announced that it will increase global capacity for high-quality single-use technologies used in the production of biologics and vaccines.

In the U.S. and Europe, the Company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19.

Avantor recently expanded its Morrisville, North Carolina, single-use facility and expects completion of a cleanroom expansion at its Devens, Massachusetts, operation by mid-year. The Company also expects to open its second European single-use facility in Hillegom, the Netherlands, by then as well.

The investment further strengthens the Company's [single-use](#) network, providing product consistency and capabilities close to bioproduction customers to help ensure efficient and uninterrupted supply.